Topamax Weight Loss Stories: How Much Weight Do People Lose?

Topiramate, sold under the brand name Topamax, reliably causes weight loss in clinical trials, with most people losing somewhere between 5 and 10 percent of their starting body weight over the course of a year. That range is real, but individual experiences vary enormously, and the story behind the numbers involves trade-offs that often go unmentioned in online forums. Topiramate was never designed as a weight-loss drug; it is an anti-seizure medication that also treats migraines. The weight loss was an unexpected side effect that researchers later studied on purpose, and understanding how it works and what it costs helps make sense of the wildly different experiences people report.

How Much Weight People Actually Lose

The most commonly cited numbers come from a year-long randomized trial of obese adults who took topiramate at three different doses. At 60 weeks, the placebo group lost about 1.7 percent of their body weight, while those on topiramate lost 7, 9.1, and 9.7 percent at the 96, 192, and 256 mg/day doses, respectively. More than half of the people on even the lowest dose lost at least 5 percent of their starting weight, compared with fewer than one in five on placebo. Roughly 30 to 44 percent of those on topiramate hit the 10-percent mark.¹

For people with type 2 diabetes, who often have a harder time losing weight due to their medications and metabolic state, a pooled analysis of multiple trials found that topiramate produced an average weight loss of about 3.4 kg (roughly 7.5 pounds) more than placebo.² That is a smaller effect than what was seen in the general obesity trials, which reflects the reality that diabetes medications and insulin resistance can blunt the drug’s impact.

When topiramate was combined with an initial low-calorie diet, the results were more dramatic. In one trial, people who started with a calorie-restricted phase and then took topiramate at 96 or 192 mg/day lost about 15 to 16.5 percent of their body weight by week 44, compared with roughly 9 percent in the placebo group.³ The takeaway: topiramate on its own produces moderate weight loss, and pairing it with dietary changes amplifies the effect considerably.

Why Topiramate Causes Weight Loss

Topiramate was not engineered to shrink your appetite. It works on brain chemistry in ways that happen to reduce how much food you eat. A narrative review of the evidence concluded that the drug reduces calorie intake, decreases fat accumulation, and lowers triglyceride and cholesterol levels. It also appears to dampen the brain’s reward response to food, which means eating simply feels less compelling.⁴

One thing topiramate does not do is speed up your metabolism. A six-month trial in obese men found that 24-hour energy expenditure, adjusted for body weight and age, was unchanged by topiramate treatment.⁵ The weight loss comes entirely from the intake side of the equation: you eat less because the drug makes food less appealing or reduces hunger signals, not because your body is burning more calories.

Higher Doses Produce More Weight Loss, But More Side Effects Too

Topiramate’s weight-loss effect is dose-dependent, and this is one of the reasons individual experiences differ so much. In dose-ranging trials, doses from 64 mg/day up to 384 mg/day were tested. The pattern is consistent: higher doses produce more weight loss, but with diminishing returns at the upper end.⁶ In the 60-week trial mentioned earlier, the jump from 96 mg/day (7 percent weight loss) to 256 mg/day (9.7 percent) was real but not as large as many people expect.⁷

The standard approach is to start low and increase gradually. In clinical trials, dosing typically began at 16 mg once daily, increased to 16 mg twice daily in the second week, and then went up by 32 mg per day each subsequent week until hitting the target dose.⁸ This slow titration is not just a formality. Side effects cluster heavily during the ramp-up phase, and starting at full dose would make the drug intolerable for many people.

The Side Effects That Dominate People’s Stories

If you read forum posts and personal accounts about Topamax, a few complaints come up over and over. The clinical literature confirms all of them. The most frequently reported side effects in the 60-week trial were neurological: tingling or numbness in the hands and feet (paresthesia), difficulty concentrating, memory problems, trouble finding words, nervousness, and a general sense of mental slowing.⁹ Most of these appeared during the dose-increase phase and improved once people stabilized, but for some they persisted.

The cognitive effects deserve special attention because they are the most common reason people decide the weight loss is not worth it. A pharmacology study confirmed that topiramate significantly reduced accuracy on working memory tasks across all difficulty levels.¹⁰ People describe this as “brain fog,” struggling to recall common words mid-sentence, or feeling mentally sluggish in ways that affect their work performance. The nickname “Dopamax” that circulates online reflects this experience, though some people find the cognitive effects mild enough to tolerate.

A less well-known but surprisingly bothersome side effect involves carbonated drinks. Topiramate alters the activity of an enzyme called carbonic anhydrase, which changes how your taste buds perceive carbonation. The result: sodas, beer, sparkling water, and anything carbonated tastes flat. One published case described a woman who experienced this immediately after starting topiramate and found it persisted through 12 months of treatment. She discovered that drinking through a straw slightly reduced the problem.¹¹ This might sound trivial, but it is one of those daily-life annoyances that shapes how people feel about staying on the drug.

Kidney Stones and Metabolic Acidosis

The carbonic anhydrase inhibition that ruins carbonated drinks also has more serious consequences. Topiramate causes a mild but measurable metabolic acidosis, meaning it shifts the blood’s chemistry toward being slightly more acidic. This leads to markedly lower citrate levels in the urine and a higher urine pH, both of which increase the risk of calcium phosphate kidney stones.¹² A case study documented this progression in a patient on long-term topiramate, where the metabolic acidosis eventually resulted in stone formation.¹³

For anyone considering topiramate long-term, staying well hydrated is not just generic health advice; it is a specific countermeasure against this risk. Doctors who prescribe topiramate for extended periods sometimes monitor blood bicarbonate levels to catch acidosis before it causes problems.

Why So Many People Quit Early

The most revealing gap between clinical trial results and real-world experiences is the dropout rate. In a real-world study of anti-obesity medication persistence, only about 27 percent of patients prescribed phentermine/topiramate were still taking it at six months.¹⁴ That was better than some alternatives but still means nearly three out of four people stopped within half a year.

An even more striking finding comes from a study of anti-obesity medication adherence: over 91 percent of patients prescribed any anti-obesity drug, including the phentermine/topiramate combination, never filled their prescription within 60 days.¹⁵ Cost, side-effect fears, and stigma around weight-loss medication all contribute to this. But among those who do start, the pattern with topiramate specifically is that discontinuation happens early, usually within the first few weeks, during the dose-titration phase when side effects are worst. In a small trial comparing topiramate and sibutramine in patients with bipolar disorder, only about one in five completed 24 weeks, and those who quit topiramate tended to do so early in treatment.¹⁶

This early-dropout pattern is important context for the success stories you see online. People who post about dramatic weight loss on Topamax are a self-selected group: they tolerated the initial side effects well enough to keep going. The experience of someone who quit after two weeks with debilitating brain fog is equally real but less likely to show up in a weight-loss forum.

What Happens When You Stop

A question that rarely gets enough attention in personal stories is what happens after you discontinue. A prospective study followed migraine patients who had lost weight on topiramate and tracked what happened after they stopped. Within six months of discontinuation, weight showed a clear trend toward returning to baseline values. By the end of the observation period, all the measured metabolic parameters had essentially reverted to where they were before topiramate began.¹⁷

This is consistent with how most weight-loss medications work. The drug suppresses appetite while you take it. Once you stop, your appetite regulation returns to its previous set point, and without ongoing behavioral changes, the weight comes back. People who have the best long-term outcomes tend to be those who use the drug as a window of opportunity to establish new eating habits and activity patterns, rather than relying on the drug’s appetite suppression indefinitely.

Topiramate for Binge Eating Disorder

Some of the most positive topiramate weight-loss stories come from people who also struggle with binge eating, and the research supports their experience. In a placebo-controlled trial of people with binge eating disorder and obesity, topiramate reduced binge frequency by 94 percent (compared to 46 percent for placebo) and produced an average weight loss of about 5.9 kg in those who completed the study.¹⁸ A second trial found similar results, with topiramate inducing binge eating remission in 58 percent of patients versus 29 percent on placebo, along with significantly greater reductions in weight and BMI.¹⁹

The dual effect on both binge frequency and weight makes topiramate somewhat unusual among medications used in this population. A review of the evidence described it as a “relatively safe and effective treatment for obese subjects with BED,” though the authors noted that the evidence base remains preliminary.²⁰ For someone whose weight problem is tightly linked to compulsive overeating episodes, topiramate addresses both the behavior and the metabolic consequence in a way that simple appetite suppressants do not.

When Topiramate Is Used to Counter Other Drug Side Effects

Another common scenario involves people who have gained weight on antipsychotic medications, which are among the most potent weight-gain-causing drugs in psychiatry. A meta-analysis of randomized trials in patients with schizophrenia found that adding topiramate significantly reduced both body weight and BMI compared to control groups.²¹ A randomized trial comparing topiramate to metformin (a diabetes drug also used off-label for antipsychotic weight gain) found that topiramate performed at least as well, with significant reductions in weight, BMI, and waist-hip ratio at every follow-up visit.²²

This is meaningful because antipsychotic-induced weight gain is a major reason patients stop taking their psychiatric medication, which can lead to relapse of serious mental illness. Having a drug that counteracts the weight gain without undermining the psychiatric treatment fills a genuine clinical need. The catch, as noted in the bipolar disorder trial, is that topiramate’s mood effects can be unpredictable in psychiatric populations, and higher ratings of manic or depressive symptoms increased the risk of early discontinuation in those patients.²³

The Phentermine-Topiramate Combination

Much of topiramate’s role in modern weight management comes through its combination with phentermine, sold as Qsymia. The pairing works because the two drugs attack weight through different mechanisms: phentermine is a stimulant that suppresses appetite, while topiramate adds its own appetite-reducing and food-reward-dampening effects at a lower dose than would be used alone, which limits side effects.

In the EQUIP trial, the higher-dose combination (phentermine 15 mg plus topiramate 92 mg) produced an average weight loss of about 10.2 kg at 56 weeks, compared with 1.4 kg for placebo. Roughly 70 percent of people on the higher dose lost at least 5 percent of their body weight, and about half lost 10 percent or more.²⁴ These numbers are more impressive than topiramate alone, which is partly why the combination product has become more commonly prescribed than solo topiramate for weight management.

How Topiramate Stacks Up Against Newer Weight-Loss Drugs

The weight-loss medication landscape has shifted dramatically with the arrival of GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). A large network meta-analysis comparing all approved weight-loss drugs found that semaglutide produced an average weight loss of about 9 kg more than placebo at 12 months, while phentermine/topiramate produced about 8.1 kg more than placebo.²⁵ The two were the top performers, with semaglutide edging ahead but phentermine/topiramate remaining competitive.

A separate systematic review placed topiramate alone at a more modest weight reduction of about 2.65 kg more than placebo, well behind semaglutide’s roughly 8.5 kg advantage and the phentermine/topiramate combination’s roughly 5.7 kg.²⁶ That same review flagged topiramate’s unique risk profile: it was associated with a higher risk of depression, while the phentermine/topiramate combination raised concerns about anxiety, sleep disturbances, and irritability.²⁷

The practical implication for someone weighing their options: topiramate alone is a modest weight-loss tool compared to the newer injectables, but it is an oral pill, it has been generic for years, and it costs a fraction of what semaglutide does. For people who cannot access or afford the newer drugs, topiramate remains a viable option, especially in combination with phentermine. The trade-off is a side-effect profile that hits the brain in ways the GLP-1 drugs do not.

Pregnancy Risk and the FDA Warning

One safety concern that stands apart from the others involves pregnancy. Data from the UK Epilepsy and Pregnancy Register found major birth defects in about 4.8 percent of pregnancies exposed to topiramate alone and 11.2 percent of those exposed to topiramate as part of a multi-drug regimen. Oral clefts were notably overrepresented, appearing in about 2.2 percent of exposed pregnancies.²⁸ A separate epidemiological study confirmed the pattern, finding that the rate of oral clefts in the topiramate-exposed group was roughly five times higher than in a reference group of women on seizure-free medication.²⁹

This risk is significant enough that the FDA has issued specific warnings, and reliable contraception is considered essential for anyone taking topiramate who could become pregnant. It is worth noting that topiramate can reduce the effectiveness of hormonal birth control, creating a double problem: the drug increases the risk of birth defects while simultaneously making some forms of contraception less reliable. Anyone using topiramate for weight loss and relying on hormonal contraception should discuss backup methods with their prescriber.